2.2 Empagliflozin significantly improved glucose tolerance and
insulin resistance in HFD/STZ-induced T2DM mice
After treatment with Empagliflozin, random blood glucose (P <
0.05) of mice in the Empagliflozin group was significantly lower than
that of the T2DM group mice (Figure 1C) and fasting blood glucose (P
< 0.05) of mice in the Empagliflozin group also significantly
decreased at the end of the treatment (Figure 1D). In addition, compared
with the T2DM group, Empagliflozin group significantly reduced blood
glucose concentration at 0 min, 15 min, 30 min, 60 min, and 120 min,
whilst the AUC of blood glucose significantly decreased both in OGTT
(Figure 1 E) and IPGTT (Figure 1F) (P < 0.05), prompting that
Empagliflozin could improve glucose tolerance and insulin resistance in
HFD/STZ-induced T2DM mice.